Optogenetics for vision restoration (2010s)
Researchers spent a decade developing optogenetic approaches that deliver light-sensitive proteins to surviving retinal cells via gene therapy. Early human trials began in the late 2010s.
Animal studies showed restored light sensitivity, but human trials required gene delivery and often high-intensity light.
The approach proved the concept that inner retinal neurons can substitute for photoreceptors, but the genetic delivery mechanism added complexity and risk.
Prosthe6 achieves the same goal as optogenetics without genetic manipulation—the drug is simply applied as drops and is reversible.
